Genes can blunt Ozempic
Researchers reported that roughly 10% of people may respond poorly to GLP‑1 drugs like Ozempic and Wegovy because of specific genetic variants tied to what investigators call “GLP‑1 resistance.” The finding suggests biological differences — not just behavior — can explain large gaps in real‑world weight‑loss responses ( ).
Glucagon-like peptide-1 drugs work by copying a gut hormone that helps people feel full, slows stomach emptying, and lowers blood sugar. A Stanford-led study published April 10 found that about 1 in 10 people carry genetic variants that can make that signal weaker, reducing how well these drugs work. (med.stanford.edu) The study focused on diabetes treatment, not weight loss alone. Researchers reported that the variants are carried by roughly 10% of the general population and were linked to poorer blood-sugar control in some patients after six months on glucagon-like peptide-1 receptor agonists. (med.stanford.edu) The team called the effect “glucagon-like peptide-1 resistance,” meaning the body has higher levels of the hormone but gets less benefit from it. The work was published in *Genome Medicine* after a decade-long international effort that included human studies, mouse experiments, and analyses of diabetes drug trial data. (med.stanford.edu) That helps explain why two people taking the same drug can get very different results. Anna Gloyn of Stanford said trial data showed some people with the variants were less able to lower blood glucose after six months, a point when doctors often switch treatments. (med.stanford.edu) The finding lands as these drugs move far beyond a niche diabetes treatment. A May 2024 KFF poll found about 12% of United States adults said they had ever taken a glucagon-like peptide-1 agonist, and 6% said they were taking one at the time. (kff.org) It also lands in a country where obesity remains common. The Centers for Disease Control and Prevention reported last month that 40.3% of United States adults had obesity in August 2021 through August 2023, with 9.7% in the severe-obesity range. (cdc.gov) The Stanford researchers were careful about what they had shown and what they had not. Their April 10 report said it is still not clear whether the same variants also blunt weight loss from higher-dose drugs such as Ozempic and Wegovy, which are increasingly prescribed for obesity. (med.stanford.edu) A separate paper published April 8 in *Nature* points in that direction. Researchers at 23andMe analyzed data from 27,885 people who reported using semaglutide or tirzepatide and found a variant in the *GLP1R* gene tied to greater weight-loss response, with about 0.76 kilograms of extra loss per copy of the effect allele. (nature.com) That *Nature* study also found genetic links to nausea and vomiting, including a *GIPR* association seen only in people taking tirzepatide, sold as Mounjaro and Zepbound. The authors said the results could help sort patients by likely benefit and side-effect risk before treatment starts. (nature.com (mediacenter.23andme.com) For now, the immediate takeaway is narrower than the hype around these drugs. The new papers suggest that when glucagon-like peptide-1 drugs fall short, the reason may sometimes be in a patient’s DNA rather than in missed doses, diet, or willpower. (med.stanford.edu)
